LIFE Science Hub
JOURNAL OF SCIENCE
EXPANDING KNOWLEDGE ABOUT NUTRITION AND HEALTH

ORIGINAL RESEARCH
ISSN 2845-7501

Regulation of Delta(5) and Delta(6) desaturases by SREBP-1 and PPARalpha

M. Moscati[1]

1 Italy

1. ABSTRACT

The analyzed study evaluated how two lipid metabolism regulators, SREBP-1 and PPARalpha, control the hepatic expression of Delta-5 and Delta-6 desaturases in mice. These enzymes insert double bonds into fatty acids and participate in the transformation of essential fatty acids into long-chain polyunsaturated fatty acids. The available results indicate that the experimental increase of SREBP-1 in the liver increased the expression of both desaturases, while the absence of SREBP-1 reduced it after refeeding. Pharmacological activation of PPARalpha also increased the expression of these enzymes.In the narrative of "The Choice to Live in Health or Illness" by Dr. A. Colonnese and R. Panzironi, this publication contributes primarily to the passage stating that SREBP-1c can increase the cellular capacity to process polyunsaturated fatty acids, including the pathway that can lead from linoleic acid to arachidonic acid. Independent studies confirm that insulin can increase the expression of SREBP-1c and desaturases in cultured human monocytes; other experiments show that SREBP can bind to the FADS2 promoter and increase its expression. However, this evidence remains predominantly cellular or animal-based. Furthermore, FADS2 activity also depends on diet, genetics, and other regulators, such as PPARalpha. The molecular link is therefore well-supported, but it does not prove on its own that hyperinsulinemia causes chronic inflammation in humans.

ONLINE ARTICLE

ARTICLE INFORMATION

Published: November 23, 2026
Updated: November 23, 2026

DOI 10.5281/zenodo.24451719

MISSION

LIFE Science Hub – Journal of Science was founded with the aim of making scientific knowledge accessible without giving up methodological rigour, quality of sources and authoritativeness of content. The journal promotes the dissemination of knowledge in the health, nutrition, medical and longevity sciences, building a bridge between the world of research and society.

Through articles, reviews, in-depth analyses and expert contributions, the Journal champions evidence-based medicine and science, fostering a correct interpretation of scientific data and countering misinformation. Every piece of content is developed with the aim of translating the complexity of research into understandable, useful and applicable information, while keeping intact the principles of accuracy, transparency and scientific independence.

Free from political, industrial and commercial influence, the journal stands as an authoritative and independent editorial space, dedicated to promoting scientific culture, professional development and the growth of health awareness among the public.

2. ANALYZED STUDY

The research question was whether Delta-5 and Delta-6 desaturases, enzymes involved in the endogenous production of long-chain polyunsaturated fatty acids, were regulated by SREBP-1 and PPARalpha. SREBP-1 is a transcription factor, meaning it is a protein that enters the cell nucleus and modulates the activation of specific genes. PPARalpha is another transcription regulator, particularly involved in the use and transformation of fatty acids.The research is relevant to sections 5.2 and 5.3.1 because it documents a precise segment of their biological chain: increased SREBP-1 activity is associated with greater expression of hepatic desaturases. In the text "The Choice to Live in Health or Illness" by Dr. A. Colonnese and R. Panzironi, this passage is used to explain how a lipogenic signal—that is, one oriented toward lipid production—can increase the cell's ability to transform essential fatty acids into longer and more unsaturated products.The study does not directly evaluate chronic hyperinsulinemia, does not measure inflammation, does not quantify prostaglandin production, and does not demonstrate that an increase in desaturases causes disease in humans. Furthermore, the available material is only the abstract: details such as the complete size of the groups, timelines, quantitative expression values, and statistical analyses are not reported in the available material.

3. MATERIALS AND METHODS OF THE ORIGINAL STUDY

The study used mouse models, with a particular focus on the liver. The authors compared transgenic mice that expressed increased levels of nuclear forms of SREBP-1a, SREBP-1c, or SREBP-2 with models lacking the SREBP-1 gene. The nuclear form is the active portion of the protein, capable of reaching the DNA and modifying gene expression.Hepatic expression of Delta-5-desaturase and Delta-6-desaturase, now commonly referred to by the genes Fads1 and Fads2, was examined. The authors also evaluated the effect of polyunsaturated fatty acids introduced through the diet and that of fibrates, drugs capable of activating PPARalpha. The comparison between fasting and refeeding in normal mice and in mice with experimental SREBP-1 alterations was also considered.The available material does not report the sample size for each group, the sex and age of the animals, the duration of dietary treatments, fibrate doses, detailed analytical methods, exclusion criteria, P values, or confidence intervals. Inflammatory endpoints, tissue concentrations of arachidonic acid, or direct measurements of the metabolic flux from linoleic acid to DGLA and arachidonic acid are not reported.

4. RESULTS

The main finding is that the experimental increase of SREBP in the mouse liver was associated with a strong activation of Delta-5-desaturase and Delta-6-desaturase expression. In simple terms, when a regulator of lipogenic genes was artificially increased, the liver produced more messenger RNA for the enzymes that modify polyunsaturated fatty acids.Conversely, the loss of the SREBP-1 gene significantly reduced the expression of both desaturases in the liver of mice refed after fasting. This comparison is relevant because refeeding is a condition in which nutritional signals normally favor lipid synthesis programs. However, the abstract does not report the effect sizes or statistical values.Dietary polyunsaturated fatty acids reduced the hepatic expression of both desaturases. In transgenic mice with maintained nuclear expression of SREBP-1c, this reduction induced by polyunsaturated fatty acids was abolished. This finding is consistent with a role for SREBP-1c in the regulation of desaturases, but it does not establish on its own that SREBP-1c is the sole regulator of the phenomenon.Finally, the administration of a fibrate significantly increased the expression of both desaturases. The authors therefore proposed a dual regulation by SREBP-1c and PPARalpha. An important result for interpretation is that, in normal mice, fasting and refeeding did not differ in the messenger RNA levels of the two desaturases: this suggests that other signals may compensate for or modify the expected effect under physiological conditions.

5. INTERPRETATION

For a cell, increasing the expression of Delta-6-desaturase means increasing one of the initial steps required to process linoleic acid, an essential

omega-6 fatty acid obtained through diet. This pathway can lead to DGLA (dihomo-gamma-linolenic acid) and subsequently to arachidonic acid through further enzymatic steps, including Delta-5-desaturase. Arachidonic acid can be incorporated into cell membranes and, when released by other enzymes, can become a precursor to lipid mediators.The segment actually documented by the analyzed study is: greater availability of SREBP-1 in the nucleus of liver cells increased expression of Fads1 and Fads2. The publication does not directly document the complete sequence of insulin SREBP-1c increase in arachidonic acid inflammation. Specifically, it does not measure insulin receptor activation, it does not measure the quantity of DGLA or arachidonic acid, and it does not measure eicosanoids, i.e., lipid mediators such as prostaglandins and leukotrienes.The term “direct target gene,” used in the book's paragraph, requires caution based solely on the available material. The abstract demonstrates functional regulation through overexpression and genetic deletion models, but it does not report experiments that directly show the physical binding of SREBP-1c to the DNA of the Fads2 gene. This part of the narrative is more precisely supported by subsequent independent cellular evidence.

6. INDEPENDENT CONFIRMATORY EVIDENCE

Independent confirmation of the link between insulin and desaturase comes from a study on cultured human THP-1 monocytes. Exposure to insulin increased the expression of SREBP-1c, FADS1, and FADS2 in a time- and dose-dependent manner. The result confirms that human monocyte cell lines can respond to insulin by simultaneously increasing the transcriptional regulator and the two desaturases. The study is consistent with the section of the book that extends the reasoning beyond the liver, but it does not prove that SREBP-1c is the sole cause of the increase in desaturases, nor does it reproduce chronic hyperinsulinemia in the human body [1].A second study provided more direct confirmation at the DNA level. In human cancer cells, chromatin immunoprecipitation experiments—a technique that verifies whether a protein is physically associated with a specific region of DNA—detected the binding of SREBP-1 to the FADS2 promoter. Experimental increase of SREBP-1 increased FADS2 RNA; inhibition of SREBP activity reduced it. This supports the concept that FADS2 may be a transcriptional target of SREBP, but the oncological model cannot be considered equivalent to a normal liver or monocytes [2].The biological function of Delta-6-desaturase in the proposed chain is supported by a mouse model with Fads2 inactivation. The deletion of the gene abolished the first step of the synthesis cascade of long-chain omega-3 and omega-6 polyunsaturated fatty acids. In other words, without FADS2, linoleic acid cannot be normally initiated along the pathway that, through successive steps, contributes to the formation of DGLA and arachidonic acid. This confirms the pivotal role of Delta-6-desaturase, but it does not prove that an increase in it automatically causes inflammation [3].Taken together, these studies build a convergent chain: insulin can increase the expression of desaturases in monocyte cells; SREBP can bind to FADS2 and promote its expression; FADS2 is essential for the initiation of the endogenous synthesis of long-chain polyunsaturated fatty acids. However, the chain remains primarily mechanistic. Clinical studies are still lacking to demonstrate, within the same biological pathway and in humans, that hyperinsulinemia increases SREBP-1c, FADS2, arachidonic acid, and inflammatory outcomes in a continuous causal relationship.

7. CONFLICTING EVIDENCE

No directly conflicting evidence of sufficient relevance has been identified; this does not prove the absence of contrary results. However, there are findings that require the narrative to be contextualized. In C57BL/6J mice, PPARalpha activation with clofibrate increased the expression of Fads1 and Fads2 in the liver, but reduced DHA concentrations in the liver, retina, and cerebral cortex phospholipids. This shows that higher enzyme expression does not allow for a linear prediction of the final amount of each fatty acid in tissues: substrate availability, degradation, transport, and other metabolic steps also matter [4].This result does not contradict the effect of SREBP-1 on desaturases. However, it scales back the idea that the induction of FADS2 alone is sufficient to demonstrate a tissue increase in arachidonic acid or inflammatory mediators. The original study also indicated that PPARalpha acts on the same desaturases and that

fasting and refeeding conditions did not fully explain their regulation. The mechanism is therefore dependent on the biological context.

8. QUADRO COMPARATIVO E SINTESI DELLE EVIDENZE

The table distinguishes the publication subject to the review from the independent evidence used to evaluate the chain described in the book.

Quadro comparativo

Reference	Study type	Population or model	Main result	Direction of evidence	Strength of evidence
Original study	Animal, genetic and pharmacological	Liver of transgenic mice, SREBP-1-deficient mice, and fibrate-treated mice	Increased SREBP-1 upregulated Fads1 and Fads2; SREBP-1 deletion reduced their expression after refeeding.	direct confirmation	moderate
[1]	Cellular	Cultured human THP-1 monocytes	Insulin increased SREBP-1c, FADS1, and FADS2 expression in a time- and dose-dependent manner.	indirect confirmation	moderate
[2]	Cellular and molecular	Human tumor cells and murine embryonic fibroblasts	SREBP-1 associated with the FADS2 promoter; its overexpression increased FADS2.	direct confirmation	moderate
[3]	Animal, genetic knockout	Fads2-deficient mice	The absence of Fads2 abolished the first step of endogenous long-chain omega-3 and omega-6 PUFA synthesis.	biologically consistent evidence	moderate
[4]	Animal and pharmacological	C57BL/6J mice with PPARalpha activation or deficiency	PPARalpha activation increased hepatic Fads1 and Fads2, but reduced DHA in multiple tissues.	discordant evidence	moderate

9. SINTESI EDITORIALE E CONCLUSIONI

CONCLUSIONS

The study analyzed directly supports, in the murine liver, that SREBP-1 increases the expression of Delta-5 and Delta-6 desaturases. This is the specific reason why it can be included in sections dedicated to the initial phase of polyunsaturated fatty acid synthesis.Independent research confirms that SREBP can regulate FADS2 and that insulin can increase desaturase expression in human monocytic cells. It is also well-supported that FADS2 constitutes an essential initial step in the endogenous synthesis of long-chain polyunsaturated fatty acids. The chain leading to arachidonic acid is biologically consistent, but the extension to human chronic inflammation requires direct clinical validation. The overall evidence is therefore supported at a mechanistic level, not as a clinical demonstration of causality.

Aggiornato al 24/11/2026. Questo contenuto riflette una sintesi divulgativa delle evidenze scientifiche al momento della pubblicazione e non sostituisce il parere medico.

10. TRANSPARENCY AND SCIENTIFIC RESPONSIBILITY

Artificial Intelligence was used solely as a tool for editorial and documentary support. All content, interpretations, bibliographic citations and conclusions have been verified, reviewed and approved by the author, who assumes full scientific responsibility for them.

The manuscript was also subjected to independent peer review prior to publication.

To ensure the greatest transparency, the complete history of the article, including the dates of submission, revision, acceptance and publication, as well as information on the peer review process, is available on the dedicated Article History page.

11. RIFERIMENTI BIBLIOGRAFICI

[1] **Insulin induces fatty acid desaturase expression in human monocytes**
Arbo et al., 2011
Scandinavian Journal of Clinical and Laboratory Investigation
DOI: https://doi.org/10.3109/00365513.2011.566350

[2] **mTOR Signaling and SREBP Activity Increase FADS2 Expression and Can Activate Sapienate Biosynthesis**
Triki et al., 2020
Cell Reports
DOI: https://doi.org/10.1016/j.celrep.2020.107806

[3] **Δ6 Desaturase (FADS2) deficiency unveils the role of ω3 and ω6 polyunsaturated fatty acids**
Stoffel et al., 2008
The EMBO Journal
DOI: https://doi.org/10.1038/emboj.2008.156

[4] **Deficiency or activation of peroxisome proliferator-activated receptor a reduces the tissue concentrations of endogenously synthesized docosahexaenoic acid in C57BL/6J mice**
Hsiao et al., 2019
Nutrition Research and Practice
DOI: https://doi.org/10.4162/nrp.2019.13.4.286